Skip to main content

Advertisement

Table 1 Summary of demographic data between control and aromatherapy arm

From: Aromatherapy for the treatment of PONV in children: a pilot RCT

  Control Aromatherapy
Age (YEAR) 8.5 (95 % CI ±3.4) 6.9 (95 % CI ±3.1)
Sex (%male) 9/18 (50 %) 12/21 (57.1 %)
ASA (I or II) 100 % 100 %
Surgery
 ENT 8/18 44 % 17/21 81 %
 Ophthalmology 5/18 27.8 % 1/21 4.8 %
 Plastic surgery 2/18 11.1 % 0/21 0 %
 Orthopaedics 0/18 0 % 0/21 0 %
 Dental 1/18 5.6 % 3/21 14.3 %
 Urology 0/18 0 % 0/21 0 %
 General surgery 2/18 11.1 % 0/21 0 %
 OR time (minutes) 66 (95 % CI ±18) 64 (95 % CI ±34)
PONV Prophylaxis
 TIVA 4/18 22 % 4/21 19 %
 Ondansetron 14/18 77.8 % 15/21 71 %
 Dexamethasone 17/18 94.4 % 18/21 85.7 %
Pain management
 Acetaminophen 17/18 94.4 % 20/21 95.2 %
 Ketorolac 6/18 33 % 2/21 9.5 %
 Morphine dose (mg/kg) 0.14 (95 % CI ±0.1) 0.13 (95 % CI ±0.09)
  1. Continuous data were expressed as mean and 95 % CI. Otherwise data expressed as percentage of subjects meeting outcome